Icon PLC (ICLR)

99.87
0.07 0.07
NASDAQ : Health Care
Prev Close 99.80
Open 99.74
Day Low/High 99.25 / 100.15
52 Wk Low/High 62.31 / 84.14
Volume 177.35K
Avg Volume 384.20K
Exchange NASDAQ
Shares Outstanding 53.78M
Market Cap 5.39B
EPS 4.80
P/E Ratio 25.24
Div & Yield N.A. (N.A)

Latest News

ICON Named By Forbes As One Of The Best Employers In America

ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been included in Forbes...

ICON Reports First Quarter 2017 Results

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter...

Parexel Is Discovering the Drugs of the Future

Parexel Is Discovering the Drugs of the Future

The midcap drug maker is finding growth as an outsourcing destination.

ICON Selected By The FDA To Validate Patient-Reported Outcome Endpoints For Antibacterial Drug Trials

ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US...

ICON Reports Fourth Quarter And Full Year 2016 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter...

ICON Issues Financial Guidance For Full Year 2017

ICON Issues Financial Guidance For Full Year 2017

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended...

ICON Further Enhances Clinical Trial Feasibility, Protocol Optimisation And Patient Recruitment Capabilities With TriNetX

ICON Further Enhances Clinical Trial Feasibility, Protocol Optimisation And Patient Recruitment Capabilities With TriNetX

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has further improved its feasibility,...

ICON Announces Appointment Of Mr. Ronan Murphy To Board Of Directors

ICON Announces Appointment Of Mr. Ronan Murphy To Board Of Directors

ICON plc , (NASDAQ:ICLR) global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Mr.

ICON Announces Executive Leadership Transition

ICON Announces Executive Leadership Transition

ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, as part of its planned succession of...

ICON Reports Third Quarter 2016 Results

ICON Reports Third Quarter 2016 Results

ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter...

ICON Completes The Acquisition Of Clinical Research Management, Inc.

ICON Completes The Acquisition Of Clinical Research Management, Inc.

ICON plc , (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced...

Icon (ICLR) Marked As A Barbarian At The Gate

Icon (ICLR) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Icon (ICLR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

ICON Reports Second Quarter 2016 Results

ICON Reports Second Quarter 2016 Results

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter...

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General...

ICON To Acquire Clinical Research Management, Inc.

ICON To Acquire Clinical Research Management, Inc.

ICON plc , (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain...

Healthcare Opportunities in Light of Brexit-Driven Selloff

Healthcare Opportunities in Light of Brexit-Driven Selloff

The sharp declines seen across the healthcare sector could present buying opportunities in companies such as Aetna, HCA, Icon and Paraxel.

ICON: DIA Live To Provide A Digital Window Into DIA Conference 2016

ICON: DIA Live To Provide A Digital Window Into DIA Conference 2016

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it will be presenting DIA Live - a social media...

New Research From ICON Demonstrates Support For 'Bring Your Own Device' Approach In Clinical Trials

New Research From ICON Demonstrates Support For 'Bring Your Own Device' Approach In Clinical Trials

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical...

ICON Announces Service Agreement With Pfizer

ICON Announces Service Agreement With Pfizer

ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc.

ICON And Pfizer Honoured As Clinical Research Team Of The Year At The Clinical And Research Excellence Awards

ICON And Pfizer Honoured As Clinical Research Team Of The Year At The Clinical And Research Excellence Awards

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical...

ICON Reports First Quarter 2016 Results

ICON Reports First Quarter 2016 Results

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter...

Goldman Sachs Gives These 4 Cheap Stocks a Thumbs Up and So Do the Charts

Goldman Sachs Gives These 4 Cheap Stocks a Thumbs Up and So Do the Charts

Investors are on the hunt for cheap stocks. Here are four that are backed up by positive charts.

14 Cheap Stocks to Buy Now From Goldman Sachs

14 Cheap Stocks to Buy Now From Goldman Sachs

These 14 inexpensive stocks are expected to have strong top-line growth in the next two years, says Goldman Sachs.

Mr. Thomas Lynch Notifies ICON Of His Retirement As Chairman And That He Will Not Stand For Re-Election To The Board Of Directors At The Annual General Meeting

Mr. Thomas Lynch Notifies ICON Of His Retirement As Chairman And That He Will Not Stand For Re-Election To The Board Of Directors At The Annual General Meeting

ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr.

ICON Selected By The International Consortium For Health Outcomes Measurement To Help Advance Value-based Healthcare

ICON Selected By The International Consortium For Health Outcomes Measurement To Help Advance Value-based Healthcare

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by the International...

ICON Reports Fourth Quarter And Full Year 2015 Results And Issues 2016 Earnings Guidance

ICON Reports Fourth Quarter And Full Year 2015 Results And Issues 2016 Earnings Guidance

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter...

ICON Selected By Genomics England To Support The Largest Genome Sequencing Project Of Its Kind For Cancer And Rare Diseases (Graphic: Business Wire)

ICON Selected By Genomics England To Support The Largest Genome Sequencing Project Of Its Kind For Cancer And Rare Diseases (Graphic: Business Wire)

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as...

ICON Secures Investment Grade Credit Ratings

ICON Secures Investment Grade Credit Ratings

ICON plc , (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported that Moody's Investors Service has assigned...